(two) is not responding to standard treatment for glaucoma or most cancers or is encountering intense side effects from treatment; and(e) If, in the course of a periodic Check out below this area, the regulatory company finds proof that a prescriber may very well be partaking in perhaps damaging prescribing patterns or procedures, the regulatory ag